Latest Capital Funding News

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.

Big gains hit wealth platforms while Zip swung the other way as early optimism didn’t stick. Dividends and buy-backs kept coming, but investors still punished stocks where the next step looks unclear.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Judo Capital Holdings has delivered a robust 1H26 result, posting a 26% half-on-half profit before tax increase and upgrading its net interest margin guidance for the second half. The bank’s SME lending franchise continues to expand rapidly, supported by strong deposit growth and a solid capital position.

GreenTech Metals has appointed James Rattenbury as CEO to spearhead development of its Munni Munni platinum group metals project, signalling a strategic push in the West Pilbara mining hub.

Macquarie Group has reported a solid third quarter for FY26, with significant profit gains in asset management and capital divisions, alongside steady growth in banking services. The group maintains a strong capital buffer, positioning itself well despite a cautious economic outlook.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Apiam Animal Health has announced a fully franked special dividend of 10 cents per share, payable before the completion of its proposed acquisition by Adamantem Capital entities. The dividend is conditional on the scheme’s effectiveness and offers shareholders potential tax benefits through franking credits.

Strickland Metals has successfully raised A$55 million through an institutional placement to accelerate exploration and advance a Pre-Feasibility Study at its Rogozna Project in Serbia.